Venturing where few have gone before to get an angle on what makes
Convincing analysts and fund managers that a stock is worth supporting is a hard enough job at the best of times. It's even more difficult when the sector remains something of a mystery. Nasdaq-listed biotech developer, Ethical Holdings, found that out to its cost a few months ago when it tried to persuade UK investors to back its proposed £20 mn London float. A lack of interest from brokers and fund managers forced Ethical to pull the flotation and abandon a linked £14 mn acquisition.
One
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
